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Following myocardial infarction (MI), myeloid cells
derived from the hematopoietic system drive a sharp
increase in systemic leukocyte levels that correlates
closely with mortality. The origin of these myeloid
cells, and the response of hematopoietic stem and
progenitor cells (HSPCs) to MI, however, is unclear.
Here, we identify a CCR2+CD150+CD48 LSK he-
matopoietic subset as themost upstream contributor
to emergency myelopoiesis after ischemic organ
injury. This subset has 4-fold higher proliferation
rates than CCR2CD150+CD48 LSK cells, displays
a myeloid differentiation bias, and dominates the
migratory HSPC population. We further demonstrate
that the myeloid translocation gene 16 (Mtg16) regu-
lates CCR2+ HSPC emergence. Mtg16/ mice have
decreased levels of systemic monocytes and infarct-
associated macrophages and display compromised
tissue healing and post-MI heart failure. Together,
these data provide insights into regulation of
emergency hematopoiesis after ischemic injury and
identify potential therapeutic targets to modulate
leukocyte output after MI.
INTRODUCTION
Leukocytes, especially monocytes and macrophages, partici-
pate integrally in all stages of ischemic heart disease (Mooreand Tabas, 2011; Swirski and Nahrendorf, 2013). During athero-
genesis, bone-marrow-derived monocytes enter the vessel wall
and give rise to macrophages and foam cells with tissue-
destructive properties (Libby, 2002). Once a plaque ruptures,
leukocytes massively accumulate in ischemic heart tissue,
where they promote healing but may also worsen tissue damage
if supplied in exaggerated numbers. An increase in circulating
white cells promotes atherosclerosis, and myocardial infarction
(MI) causes acute leukocytosis, which correlates closely with
cardiovascular mortality (Swirski and Nahrendorf, 2013). How
organ ischemia activates the hematopoietic system is poorly
understood.
The majority of hematopoietic stem cells (HSCs) are quiescent
and enter the cell cycle only sparingly to self-renew and produce
progeny (Wilson et al., 2008). Even though most HSCs are
dormant at any given time point, they can be activated by a sys-
temic insult such as infection (Essers et al., 2009; Baldridge et al.,
2010; Takizawa et al., 2011). Moreover, HSCs are able to
reversibly change between quiescence and proliferation states
(Glauche et al., 2009). However, an ‘‘effector subset’’ that drives
the proliferation response after a systemic insult has not been
identified. We do not know how HSCs respond to MI, which is
the most common cause of death. The HSC response to tissue
injury may be of particular relevance to patients that survive an
ischemic insult because myeloid progeny play a major role in tis-
sue repair and patient recovery (Swirski and Nahrendorf, 2013).
Here we describe a CD150+CD48LineageSca-1+c-Kit+ (LSK)
subset that can be identified by flow cytometry staining for the
chemokine receptor CCR2 (CCR2+ HSPCs). After myocardial
ischemic injury or exposure to bacterial lipopolysaccharide
(LPS), CCR2HSCs remain quiescent while CCR2+HSPCs repli-
cate robustly. These observations identify the hematopoieticCell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc. 477
Figure 1. Activation of HSPCs after MI
(A) CD48CD150+ HSC proliferation measured by BrdU incorporation with flow cytometry in steady state (No MI) and at different time points after MI (permanent
coronary ligation, n = 8–29 per group). Hours refer to the time of BrdU injection after coronary ligation.
(B) Proliferation imaged by 18F-FLT-PET/CT in bone marrow 2 days after MI. Arrow heads indicate increased PET signal in the vertebral marrow (n = 5–6 per
group).
(C) Flow cytometric gating strategy for CCR2+CD150+CD48 LSKs, LRPs, and MPPs.
(D) Proliferation of CD48CD150+CCR2+ and CCR2 LSKs in steady state and 48 hr after MI (n = 5–17 per group) in mice. Data are shown as mean ± SEM,
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1.system’s point of activation during severe stress andprovide new
insight into the pathogenesis of a highly prevalent disease.
RESULTS
MI Triggers Myelopoiesis in the Bone Marrow by
Activating CCR2+ HSPCs
MI results in leukocytosis andmassive infiltration ofmyeloid cells
into the injured heart (Swirski and Nahrendorf, 2013). Since
myeloid cells in the infarct turn over in <24 hr (Leuschner et al.,
2012), the high demand must be met by hematopoietic organs,
and new cells arise from hematopoietic stem and progenitor
cells (HSPCs). By following the bone marrow hematopoietic line-
age upstream, we found increased proliferation of even the most
primitive progenitor cells in mice with coronary ligation. In the
femur, CD150+CD48 HSCs (Figure 1A) and LineageSca-1+c-
Kit+ cells (LSKs) (Figure S1A) incorporate the highest levels of
the proliferation marker BrdU 48 hr after MI. Because BrdU
may be mitogenic (Takizawa et al., 2011), we confirmed this pro-
liferation peak with cell-cycle analysis on day 2 after coronary
ligation while comparing to controls without ischemia. After MI,478 Cell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc.the percentage of quiescent HSCs and LSKs in G0 phase de-
creases while more HSCs and LSKs proliferate (G1 and S-G2-
M phases) (Figures S1B and S1C). This results in more numerous
HSCs, LSKs, multipotent progenitor cells (MPPs), and lineage-
restricted progenitors (LRPs) in the femur bone marrow on day
3 after MI (Figure S1D). 18F-FLT-PET/CT, a clinical imaging
method for measuring cellular proliferation in cancer (Shields
et al., 1998), detected increased signal in mouse vertebrae, indi-
cating that MI induces widespread bone marrow response (Fig-
ure 1B) and that imaging may be used to monitor hematopoiesis.
While the vast majority of HSCs are quiescent, we hypothe-
sized—in line with recent reports on HSC heterogeneity in the
steady state (Mossadegh-Keller et al., 2013; Oguro et al.,
2013)—that MI activates a specific HSC subset. Newly made
monocytes rely on the chemokine receptor CCR2 for their depar-
ture from the bone marrow (Serbina and Pamer, 2006) and
recruitment to the infarct (Dewald et al., 2005). CCR2 also iden-
tifies certain cardiac macrophage subsets (Epelman et al., 2014)
and guides HSPCs to the inflamed peritoneum (Si et al., 2010).
We hypothesized that a CCR2+ HSPC subset might give rise to
the systemic increase in CCR2+ leukocytes during MI. Indeed,
Figure 2. Human CCR2+ Expression in HSCs
(A) CCR2 expression on both human non-classical monocytes and classical monocytes in the blood and CMPs, GMPs, and HSCs in the bone marrow harvested
from the sternum during open heart surgery. The gating strategy for human HSCs is shown. The uppermost right panel shows isotype control staining for the
CCR2 antibody.
(B) Proliferation of human CCR2+ and CCR2 HSPCs (n = 5 per group).
Data are shown as mean ± SEM, **p < 0.01. Patient characteristics are listed in Table S1.about 15% of CD48CD150+ HSCs express CCR2 at high levels
(Figure 1C). To test the specificity of FACS staining for CCR2,
we examined HSCs in CCR2+/RFP mice, in which we detected
a similar RFP+ HSC frequency of 15% (Figure S1E). CCR2+
CD150+CD48 LSKs also contain higher levels of CCR2 mRNA
when compared to their CCR2 counterparts (Figure S1E).
CCR2+HSPCsproliferate significantlymore thanCCR2HSCs
in steady state, as assessed by BrdU incorporation (Figure 1D)
and BrdU-independent cell-cycle analysis (Figure S1F). 48 hr
after coronary ligation, the gap in proliferative activity widens in
these subsets; the fraction of BrdU+CCR2+ CD150+CD48
LSKs increases to >40% whereas the fraction of BrdU+CCR2
CD150+CD48 LSKs remains at low levels (Figure 1D). However,
HSCproliferation inCCR2/micewas similar to that in wild-type
mice (Figure S1G). Analysis of human HSCs harvested from the
sternal bone marrow of patients (Table S1) undergoing median
sternotomy for open heart surgery confirmed CCR2 expression
by an HSC subset (Figure 2A) and the higher proliferation of
CCR2+CD150+CD48 LSKs (Figure 2B) observed in mice.
Electron microscopy revealed that murine CCR2+CD150+
CD48 LSKs aggregate ribosomes (Figure 3A), indicating active
protein synthesis (Hardesty et al., 1963) in association with
increased cell proliferation. Depending on their proliferative
activity, HSPCs may reside in different bone marrow regions,
with more primitive and quiescent cells locating to the vicinity
of bone (Lo Celso et al., 2009; Nombela-Arrieta et al., 2013; Mor-
rison and Scadden, 2014). Intravital microscopy after co-transfer
of CCR2 and CCR2+CD150+CD48 LSKs labeled with spec-
trally distinct fluorescent membrane dyes mapped the cells’ dis-
tribution in the skull calvarium bonemarrow. Matching their state
of quiescence and activity, the majority of CCR2 HSCs reside
near the endosteum, whereas CCR2+ HSPCs are more distant
(Figure 3B). We next examined similarities and differences
between CCR2+ and CCR2CD150+CD48 LSKs sorted from
steady-state mouse bone marrow using Affymetrix microarrays.
In a transcriptome-wide unsupervised hierarchical clustering
analysis, CCR2+ and CCR2CD150+CD48 LSKs clearly segre-gated, pointing to global differences in their gene expression
programs (Figure 3C and Table S2). Because rescue capacity
distinguishes HSCs from hematopoietic progenitor cells, we
investigated if CCR2+CD150+CD48 LSKs can rescue lethally
irradiated mice. To this end, we injected lethally irradiated mice
with either 100 CCR2 or 100 CCR2+CD150+CD48 LSK and
Sca-1-depleted supportive bone marrow cells. CCR2 HSCs
rescued seven out of eight mice, whereas CCR2+ cells rescued
six out of ten mice (Figure 3D). 120 days after the first transplan-
tation, both CCR2 and CCR2+CD150+CD48 LSK reconstitu-
tion gave rise to multilineage chimerism, which was biased
toward the myeloid lineage in mice that received CCR2+ cells
(Figure S2A). In a secondary host, which received either 100
CCR2 or CCR2+CD150+CD48 LSKs isolated from primary re-
cipients, CCR2+ cells exhausted their self-renewal capability
while CCR2 HSCs did not (Figure S2B). In contrast to the
primary host, CCR2+CD150+CD48 LSK-derived leukocyte
chimerism was markedly reduced 5 weeks after secondary
transplantation (Figure S2C). We used a limiting dilution assay
to determine the number of functional HSCs within CCR2 or
CCR2+CD48CD150+ LSKs harvested from steady-state bone
marrow (Figure 3E). Irradiated recipients received dilutions be-
tween 31 to 1,000 cells isolated by flow cytometry. Four months
later, less than 0.1% multilineage blood chimerism determined
the non-responding fraction of recipient mice. The frequency
of functional HSCs was 6.5-fold higher within CCR2 HSCs
when compared to the CCR2+ subset (Figure 3E). However, a
second limiting dilution assay indicated that the frequency of
functional HSCs is unchanged in CCR2/ bone marrow (Fig-
ure S2D). All together, these data suggest that CCR2+ HSPCs
represent a functionally distinct subset with reduced self-
renewal capacity in secondary hosts, and that this HSPC subset
undergoes preferential activation during MI. The data further
implicate that CCR2 may serve as a marker to identify this
actively proliferating HSPC subset in mice and humans. How-
ever, genetic deficiency of CCR2 alters neither HSC proliferation
nor frequency.Cell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc. 479
Figure 3. CCR2+ HSPC Phenotype, Loca-
tion, and Function
(A) Electronmicroscopy images of cell subsets (left
panel) and magnified cytosol showing distribution
of ribosomes (right panel). The bar graph shows
ribosome aggregation in subsets (one-tail Wil-
coxon rank sum test, p = 0.036) (n = 6 ROIs in three
CCR2+ and n = 13 ROIs in five CCR2 HSPCs).
(B) DiO-labeled CCR2 and DiD-labeled CCR2+
CD150+CD48 LSKs were imaged in the skull with
intravital microscopy 1 day after transfer (n = 13–
27 cells in two mice per group). DiO-labeled
CCR2 HSCs are green, DiD-labeled CCR2+
HSPCs are white, blood pool is red, and osteo-
blasts are blue. The scale bar represents 20 mm.
(C) Hierarchical clustering dendrogram based on
whole-transcriptome microarray data of CCR2+
and CCR2CD150+CD48 LSKs sorted from
steady-state bone marrow (three replicates per
group).
(D) Survival curve of lethally irradiated mice re-
constituted with CCR2 (n = 8), CCR2+ (n = 10),
CD150+CD48 LSKs, or MPPs (n = 4).
(E) Limiting dilution assay determined func-
tional HSC frequency among CCR2 and CCR2+
CD150+CD48 LSKs in wild-type bone marrow.
Multilineage blood chimerism of 0.1% or higher
served as a cut-off value to determine responders
(p < 0.001 for difference in frequency). Table lists
dilution steps, numbers of mice analyzed 4months
after HSC transfer, and number of responders.
Data are shown as mean ± SEM, *p < 0.05, ***p <
0.001. See also Figure S2 and Table S2.Myeloid Translocation Gene onChromosome 16 Activity
in CCR2+ HSPCs
To understand themolecular mechanisms underlying the distinct
functions of CCR2+CD150+CD48 LSKs, we contrasted their
gene expression profiles with CCR2CD150+CD48 LSKs using
gene set enrichment analysis. Of 78 gene sets that were upregu-
lated inCCR2+HSPCs at a 25% false discovery rate (FDR) cutoff,
the most significant set contained genes regulated by myeloid
translocation gene on chromosome 16 (Mtg16), a transcriptional
co-repressor required for hematopoietic progenitor cell fate deci-
sions and early progenitor cell proliferation (Chyla et al., 2008).
Specifically, genes previously found downregulated inMtg16/
mouse bone marrow progenitor cells were enriched in CCR2+
HSPCs, while genes upregulated uponMtg16 knockout were en-
riched in CCR2HSCs (ranked as fourth significant among 1,222
gene setswith anFDR<25%) (Figure 4A).WeperformedqPCR to
determine any difference in the subsets’ expression ofMtg16 or
the transcription factors to which it binds (Hofmann et al., 2002;
Okuda et al., 2001; Semerad et al., 2009; Summers et al., 2013;
Young et al., 2004). CCR2+ HSPCs express significantly higher
levels of Mtg16 than CCR2 HSCs (Figure 4B). Of the regulatory
factors, Prkar2a, which increases in HSCs of patients with mye-
lodysplastic syndrome (Hofmann et al., 2002), was higher in
CCR2+ HSPCs (Figure S3A). Mtg16/ mice have fewer CCR2+
HSPCs while CCR2 HSC levels appear unchanged (Figure 4C).
The paucity of CCR2+ HSPCs inMtg16/mice associates with
decreased HSC proliferation after MI (Figures S3B and S3C)
and fewer monocytes and macrophages in the blood (Figure 4D)480 Cell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc.and infarct tissue (Figure 4E) on day 3 after coronary ligation.
In line with this observation, Mtg16 expression was higher in
HSCs during the active S-G2-Mphases of the cell cycle in steady
state (Figure S3D) and after a 5FU challenge (Figures S3E–S3G),
indicating an association ofMtg16 and cell proliferation. Of note,
proliferating CCR2-deficient HSCs are still able to increase
Mtg16 expression after MI, demonstrating that CCR2 does not
regulateMtg16 expression (Figure S3H). To evaluate the relative
contribution to myelopoiesis after MI, we injected GFP+ CCR2
or CCR2+CD150+CD48 LSKs into CD45.1 mice on day 4 after
coronary ligation. Four days after transfer, we investigated the
progeny of transferred cells in the recipient’s blood and infarcts
(Figure 4F). We found significantly higher numbers of leukocytes
produced by CCR2+CD150+CD48 LSKs when compared to
progeny of transferred CCR2CD150+CD48 LSKs. Almost all
infarct leukocytesderived fromCCR2+HSPCsweremyeloid cells
(Figure 3F). These data indicate that CCR2+ HSPCs contribute to
the infarct myeloid cell population; however, the functional impli-
cations for recovery after MI were still unclear. To explore this
question, we investigated infarct healing in Mtg16/ mice with
severely reduced CCR2+CD150+CD48 LSKs. Seven days after
coronary ligation, protease activity, which is tightly linked to
myeloid cell function, was lower in infarcts ofMtg16/mice (Fig-
ure 4G). Serial cardiacMRI reported a comparable infarct size on
day 1 after coronary ligation in wild-type andMtg16/mice (Fig-
ure S3I), but left ventricular dilation accelerated inMtg16/mice
(Figure 4H). In parallel, immunoreactive staining for the macro-
phage surface marker CD68, myofibroblasts, and collagen-1
Figure 4. Role of Mtg16 in Myelopoiesis
(A) Gene set enrichment analysis showing that CCR2+ HSPCs express genes that are downregulated in hematopoietic stem and progenitor cells in Mtg16/
mice, while CCR2 HSCs express genes that are upregulated in Mtg16/ (FDR q < 0.001 in both cases).
(B) Mtg16 mRNA expression in HSCs normalized to Gapdh (n = 6 per group).
(C) Percentage of CCR2+ and CCR2CD150+CD48 LSKs in wild-type and Mtg16/ mice in steady state (n = 7–8 per group).
(D and E) FACS quantification of myeloid cells 3 days after MI in the blood (D) and infarct (E) of wild-type and Mtg16/ mice (n = 4–6 per group).
(F) Seven thousandCCR2+ or CCR2CD150+CD48 LSKswere sorted fromGFP+ bonemarrow and adoptively transferred into CD45.1 C57B/6 on day 4 after MI.
Four days after transfer, progeny of GFP+ cells were analyzed in the blood and infarct (n = 4 per group).
(G) In vivo protease imaging in wild-type and Mtg16/ mice on day 7 after MI (infarct indicated by yellow circle) (n = 10–12 per group).
(H) Change in end-diastolic volume (D EDV) between day 1 and 21 after MI in wild-type andMtg16/micemeasured with cardiacMRI. Original MR images show
representative end-diastolic mid-ventricular short axis view 21 days after MI (n = 6–7 per group).
Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.decreased 7 days after coronary ligation in infarcts of Mtg16/
mice (Figure S3J). Taken together, these data link an insufficient
number of CCR2+ HSPCswith decreasedmacrophage supply to
the ischemic wound, which impaired infarct healing and recovery
after ischemic organ injury.
Hierarchy and Lineage Bias
Gene set enrichment analysis indicated that CCR2 HSCs
express genes associated with upstream HSCs (ranked 19th
among 1,222 significant gene sets) (Figure 5A), thereby suggest-
ing these cells hold a higher hierarchical position. Principal com-ponents analysis of the whole transcriptome corroborates this
observation: CCR2 HSCs are in proximity to upstream CD34
LSKs while CCR2+ HSPCs distribute closer to myeloid cells (Fig-
ure 5B). To test directly the subset’s lineage relationships, we co-
transferred CD45.2 CCR2 and CD45.1 CCR2+CD150+CD48
LSKs into lethally irradiated mice and investigated reconstitution
4 months later. CCR2 HSCs have a higher reconstitution
capability and can generate CCR2+ HSPCs (Figure 5C). CCR2+
CD150+CD48 LSKs failed to give rise to CCR2 CD150+CD48
LSKs, confirming that CCR2 HSCs are more primitive (Fig-
ure 5C). Since HSCs harvested fromCD45.2+mice engraft betterCell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc. 481
Figure 5. Lineage Relationship between CCR2+ and CCR2–CD150+CD48– LSKs
(A) Gene set enrichment analysis for HSC genes shows enrichment in CCR2 HSCs (FDR q = 0.001).
(B) Principal components analysis. Projection of CCR2+ and CCR2CD48CD150+ LSKs into the same space as mouse HSCs, leukocytes, and erythrocytes
shows differentiation of CCR2+CD150+CD48 LSKs along the myeloid lineage.
(C) Upper panel: Experimental design for competitive bone marrow reconstitution with 100 CCR2+ and CCR2CD150+CD48 LSKs. Lower panel: plots showing
HSC chimerism in the bone marrow and percentage of CCR2+CD150+CD48 LSKs derived from transferred cells. The bar graphs depict quantified flow
cytometric data (n = 4 per group).
(D) Blood chimerism in myeloid cells derived from transferred HSCs 4.5 months after bone marrow reconstitution (n = 3 per group).
(E) mRNA levels of myeloid (PU.1 andCebpa) and lymphoid (Ikaros) transcription factors in FACS-isolated CCR2+ andCCR2CD150+CD48 LSKs, normalized to
Gapdh (n = 3–10 per group).
Data are shown as mean ± SEM, *p < 0.05, **p < 0.01. See also Figure S4.thanCD45.1 HSCs (Purton and Scadden, 2007), we switched the
HSC subtype’s sources; however, CCR2 HSCs still reconsti-
tuted better (data not shown). Slamf3 (CD229) and Slamf4
(CD244) HSCs were previously classified as quiescent HSCs
(Oguro et al., 2013), and our observation that CCR2 HSCs
contain higher percentages of Slamf3 and Slamf4 cells (Fig-
ure S4A) supports that classification. In contrast to most MPPs
(Yang et al., 2005), CCR2+ HSPCs do not express FLK-2 (Fig-
ure S4B), which, together with expression of the SLAM family
markers and long-term multilineage repopulation capacity in
lethally irradiatedmice, distinguishes CCR2+ HSPCs from down-
streamMPPs on phenotypic and functional levels. After reconsti-482 Cell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc.tuting irradiated recipients, CCR2+ HSPCs give rise to a higher
percentage of CD11b+ cells, which indicates their myeloid bias
(Figure 5D and Figures S4C–S4E). Consistent with this finding,
CCR2+ HSPCs express higher levels of the transcription factors
PU.1 and Cebpa (Figure 5E). In contrast, CCR2 and CCR2+
CD150+CD48 LSKs comparably express Ikaros, a lymphoid
transcription factor (Figure 5E).
During MI Bone Marrow Preferentially Releases CCR2+
HSCs
CCR2 is involved in monocyte (Charo and Peters, 2003) and
progenitor cell (Si et al., 2010) migration. Accordingly, genes
Figure 6. Migration of CCR2+CD150+CD48– LSKs from the Bone Marrow in Steady State and after MI
(A) Gene set enrichment analysis for chemokines and chemokine receptors shows enrichment in CCR2+CD150+CD48 LSKs (FDR q < 0.05).
(B) Percentage of CCR2+ and CCR2CD150+CD48 LSKs in the blood during steady state at Zeitgeber 17 (midnight) and Zeitgeber 5 (noon) (n = 4 per group).
(C) CD45.1 and CD45.2 mice were analyzed after 5 weeks of parabiosis. Only CCR2+CD150+CD48 LSKs migrated to the other bone marrow of the other
parabiont. The plots and the bar graph depict the percentage of CCR2+ host and migratory CD150+CD48 LSKs in the bone marrow (n = 5 per group).
(D) LSKs in blood in CCR2/ and wild-type mice 4 days after the inducement of myocardial infarction (MI) (n = 5–12 per group).
(E) Upper panel: experimental design to investigate CCR2-dependent emigration from the bone marrow after MI. Lower panel: percentage of LSK chimerism in
the blood (normalized to bone marrow chimera) 4 days after MI (n = 5 per group).
(F) Post-MI HSC release into blood is dominated by CCR2+CD150+CD48 LSKs. FACS plots are gated on HSCs. The bar graph depicts the increase of absolute
HSC numbers in blood from steady state to day 3 after MI (n = 8–9 per group). Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
See also Figure S5.associated with cellular migration are enriched in CCR2+
CD150+CD48 LSKs (ranked ninth out of 78 significant gene
sets) (Figure 6A). Even though only 15% of bone marrow HSCs
express CCR2, most (>90%) LSKs and HSCs in the blood and
spleen are CCR2+ (Figure S5A). HSCs release from the bone
marrow following circadian oscillations (Me´ndez-Ferrer et al.,
2008) (Figure 6B), with a migration peak at noon (Zeitgeber 5).
We found that the majority of LSKs released in steady-state
circadian oscillation express CCR2 at high levels (Figure 6B).
To investigate HSC migration during steady state, we put
CD45.2 and CD45.1 mice into parabiosis (Figure 6C and Fig-
ure S5B). After 5 weeks of joint circulation, we evaluated the
expression of CCR2 on HSCs that hadmigrated from onemouse
to the bone marrow of the other. All CD45.1+ parabiont-derived
HSCs in the bone marrow of CD45.2 mice expressed CCR2 at
high levels (Figure 6C). Together, these data indicate that only
CCR2+ CD150+CD48 LSKs have migratory capacity in the
steady state and confirm our adoptive transfer data (Figure 5C)
showing that CCR2+ cells do not revert to CCR2 HSCs.Post-MI HSPC release from the bone marrow enables
extramedullary amplification of myelopoiesis and exacerbates
inflammation in atherosclerotic plaque due to outsourced and
accelerated splenic leukocyte production (Robbins et al., 2012;
Leuschner et al., 2012; Dutta et al., 2012). Because we found
that most migrating HSCs are CCR2+ during steady state, we
tested whether infarct-induced HSC release also depends on
CCR2. We induced MI in CCR2/ mice and found impaired
LSK release into blood (Figure 6D and Figure S5C). Knocking
down CCR2 in HSCs with lipidoid nanoparticle-delivered siRNA
(Leuschner et al., 2011) reduces the MI-induced LSK release
(Figures S5D–S5F) and consecutive splenic seeding (Fig-
ure S5G). In fact, siRNA may be an avenue for therapeutic
intervention aiming to reduce the production and supply of in-
flammatory leukocytes. To investigate further if CCR2/ LSKs
can leave the bone marrow, we generated mixed bone marrow
chimeras by reconstituting lethally irradiated GFP+ mice with
both CCR2/ and CCR2+/+ HSCs (Figure 6E). Upon induction
of MI, only CCR2+/+ LSKs leave the bone marrow (Figure 6E).Cell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc. 483
Figure 7. CCR2+ HSPCs after LPS Treatment
(A) Fold change of CCR2+ and CCR2CD150+CD48 LSK number in bonemarrow of LPS-injected mice compared to PBS-injected controls at 4 hr after injection
(n = 4 per group).
(B) Fold change of proliferation 4 hr after injection of LPS (n = 6 per group).
(C) Steady state TLR4 and TLR2 expression levels on HSCs (n = 9 per group).
Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6.In wild-type mice, the increase of circulating HSPCs on day 3
after MI relies exclusively on CCR2+CD150+CD48 LSKs (Fig-
ure 6F). To investigate if stromal bone marrow cells produce
more CCL2 after MI, we isolated endothelial and mesenchymal
stem cells from the bonemarrow on day 4 after coronary ligation,
as both are potential sources for the chemokine (Shi et al., 2011).
After MI, only endothelial cells express elevated levels of CCL2
mRNA (Figure S5H), indicating that CCL2 produced by endothe-
lial cells could mobilize CCR2+ HSPCs from their niche.
CCR2+ HSPCs Are Activated after LPS and HMGB1
Challenge
Finally, we wondered if the role of CCR2+ HSPCs is specific to MI
or whether this cell subset has broader functions. Thus, we chal-
lenged mice with LPS, an endotoxin contained in the cell walls of
Gram-negative bacteria. CCR2+ HSPCs expanded in the bone
marrow 4 hr after injection of this Toll-like receptor ligand
(Figure 7A). Measuring BrdU incorporation, we found that only
CCR2+ HSPCs increase proliferation after LPS challenge (Fig-
ure 7B). Preferential activation of CCR2+ HSPCs at 4 hr after LPS
injection suggests that this subset expresses high levels of recep-
tors that sense danger-associated molecular patterns (DAMPs).
Accordingly, CCR2+ CD150+CD48 LSKs express significantly
higher levels of TLR4 and TLR2 when compared to CCR2
CD150+CD48 LSKs (Figure 7C). In the context of cardiovascular
disease, ischemic injury may release DAMPs that ligate TLRs.
Indeed, CCR2+ HSPCs increase TLR4 expression after MI (Fig-
ure S6A). Injection of HMGB1, which is released by cardiomyo-
cytes during acute MI (Arslan et al., 2011), enhances CCR2+
HSPC proliferation (Figure S6B).
DISCUSSION
Thewhite blood count is one of themost frequently orderedmed-
ical tests, reflecting its clinical value. In cardiovascular patients,
leukocytosis and monocytosis closely correlate with survival.
We increasingly understand why: inflammatory monocytes and
macrophages, when overproduced, damage the arterial wall
and vital organs such as the heart afterMI or the brain after stroke.484 Cell Stem Cell 16, 477–487, May 7, 2015 ª2015 Elsevier Inc.We have surprisingly limited understanding of mechanisms lead-
ing to increased leukocyte count in cardiovascular patients.
Chronic leukocytosis affiliated with hyperlipidemia arises from
perturbedcholesterol efflux,whichmakeshematopoietic progen-
itors cycle more vigorously (Yvan-Charvet et al., 2010) and gives
rise to progressively elevated monocyte counts in mice with
atherosclerosis (Swirski et al., 2006; Tacke et al., 2007). MI in-
duces enhanced extramedullary myelopoiesis due to increased
progenitor cell traffic between the marrow and the spleen (Dutta
et al., 2012). Even though insufficient and exuberant leukocyte
production afterMI associateswith poorer prognosis (Nahrendorf
et al., 2010), the mechanisms that link ischemic injury to changes
in hematopoiesis at the stem cell level have remained obscure.
This study identifies preferential activation of a CCR2+CD150+
CD48 LSK subset during MI or exposure to a bacterial danger
signal, LPS. In contrast, CCR2CD150+CD48 LSKs remain
quiescent in stress conditions. Thus, CCR2+CD48CD150+
LSKs represent the most upstream point of increased myelo-
poiesis after MI. In contrast to retrospectively identifiable
myeloid-restricted progenitors with long-term repopulation ac-
tivity (Yamamoto et al., 2013), CCR2 serves as a cell surface
marker to prospectively identify a highly active cell population
within the CD150+CD48 SLAM HSC gate. CCR2 also partici-
pates functionally by mediating migratory cell activity during MI.
A fewHSPCsmigrate even in the steady state, possibly to survey
peripheral organs (Massberg et al., 2007). Of direct relevance to
the present observations, CCR2+ cells dominate in this migratory
population. Moreover, CCR2+ HSPCs express receptors of
DAMPs such as TLR4 and TLR2. They increase expression of
these receptors further after MI, rendering them sensitive to
danger signals, suchasHMGB1, released from thedeadmyocar-
dium. In addition, CCR2+CD150+CD48 LSKs are also preferen-
tially activated after LPS challenge.
After MI, activity of the sympathetic nervous system triggers
bone marrow release of HSPCs into circulation in larger
numbers, thus enabling the outsourcing of inflammatory cell pro-
duction to the spleen (Dutta et al., 2012). Splenic myelopoiesis
replenishes the organ’s monocyte reservoir, which supplies cells
in the first 24 hr after injury (Swirski et al., 2009) but also supports
continued contribution of cells to the heart (Leuschner et al.,
2012). In healing infarcts and other wounds, the initial need for
macrophages is followed by the necessity for resolution of
inflammation. The observation of impaired infarct healing in
Mtg16/ mice with an insufficient supply of infarct macro-
phages underscores the cell’s contribution to tissue repair.
However, if inflammation resolution is delayed, infarcts rupture
and heart failure occurs. Thus, the supply of inflammatory cells,
which are initially important for clearing dead cells and the
orchestration of tissue repair, should wind down as wound heal-
ing progresses to proliferative stages. The post-MI bone marrow
release of CCR2+CD150+CD48 LSKs, which excel at migration
and myeloid cell production but have a lower self-renewal
capacity than CCR2CD150+CD48 LSKs, may hypothetically
amount to a program of expanded leukocyte production with a
built-in exit strategy. If likewise released, CCR2 HSCs would
ignite indefinite extramedullary hematopoiesis and thus perpet-
uate systemic inflammation, a complication that is likely avoided
by limiting bone marrow cell exit to CCR2+ HSPCs that exhaust
in secondary transplantation assays.
Since CCR2+CD150+CD48 LSKs do not rescue secondary
hosts, they are not long-term HSCs. CCR2+CD150+CD48
LSKs share phenotypic markers with short-term HSCs, as they
express CD34, but not FLK-2, and resemble short-term HSCs
in their failure to repopulate secondary hosts (Yang et al.,
2005). CCR2+CD150+CD48 LSKs generatemultilineage chime-
rism in primary recipients 4 months after reconstitution and
rescue lethally irradiated primary hosts, which places them func-
tionally above short-term HSCs according to some definitions
(Reya et al., 2001; Challen et al., 2009); however, they resemble
recently described upstreamMPP-1 (Cabezas-Wallscheid et al.,
2014). We therefore refer to these cells as ‘‘CCR2+ HSPCs.’’
Unchanged functional HSC frequency and proliferation in
CCR2/ mice indicates that CCR2 does not regulate stem cell
replication after MI. Rather, we identify Mtg16 as amolecular de-
cision node in HSPCs and, consecutively, in monocyte produc-
tion. The dampened post-MI myelopoiesis and compromised
infarct healing in Mtg16/ mice may be caused by the lack of
the CCR2+ HSPC subset but could additionally reflect compro-
mised responses of downstream progenitors. Despite growing
evidence of inflammation’s importance in ischemic heart dis-
ease, specific anti-inflammatory therapeutic approaches have
only begun to emerge. The data presented here indicate that tar-
geting CCR2+ HSPCs, for instance via CCR2 or Mtg16, might
reduce emergency monocyte production, curb macrophage
oversupply, and limit excessive tissue destruction during acute
inflammation triggered by ischemic injury.EXPERIMENTAL PROCEDURES
Animal Models and Surgeries
All mouse studies were approved by the Subcommittee on Animal Research
Care at Massachusetts General Hospital. C57BL/6J, C57BL/6-Tg(UBC-GFP)
30Scha/J, B6.SJL-Ptprca Pepcb/BoyJ (CD45.1), B6.129S4-Ccr2tm1fc/J
(CCR2/), and B6.129(Cg)-Ccr2tm2.1Ifc/J (CCR2+/RFP) mice were purchased
from Jackson Laboratory. For all experiments, 4- to 5-month-old mice were
used. To induce MI, thoracotomy in the fourth left intercostal space was per-
formed after intubation and ventilation with 2% isoflurane. The left coronary
artery was permanently ligated with a monofilament nylon 8-0 suture, and
the thorax was closed with a 5-0 suture. For parabiosis, an incision wasmade on the skin on the lateral sides of mice starting from the ear reaching
the tail. Corresponding scapulae were joined using a 6-0 suture. A 0.5 cm inci-
sion was made on the abdomen and approximated with a 6-0 suture. The skin
was sutured with mono-nylon 6-0 (Ethicon).
Flow Cytometry
Cells diluted in 300 ml of FACS buffer were stained with fluorochrome-labeled
antibodies against mouse leukocyte markers and hematopoietic stem and
progenitor cell markers. For leukocyte staining, a phycoerythrin (PE) lineage
cocktail was used, which contains antibodies directed against CD90 (clone
53-2.1), B220 (clone RA3-6B2), CD49b (clone DX5), NK1.1 (clone PK136), Ly-
6G (clone 1A8), and Ter-119 (clone TER-119). Leukocytes were stained with
anti-mouse CD11b (clone M1/70), CD11c (clone HL3), F4/80 (clone BM8) and
Ly6C (clone AL-21). Monocytes were identified as (CD90/B220/ CD49b/
NK1.1/Ly-6G/Ter119)low CD11bhigh F4/80low CD11cneg/low Ly-6Chigh/low. For
stem and progenitor cell staining, we used biotin-conjugated antibodies
against CD11b (clone M1/70), CD11c (clone N418), and IL7Ra (clone A7R34)
in addition to the lineage antibodies used for leukocyte staining. The cells
were then stained with anti c-Kit (clone 2B8), Sca-1 (clone D7), CD16/32 (clone
2.4G2), CD34 (clone RAM34), CD115 (clone AFS98), CD150 (9D1), CD48
(HM48-1), and CCR2 (RandD Biosystems clone: 475301; abcam: ab21667).
HSCs were identified as lineagelow c-Kithigh Sca-1high CD150+CD48.
Downstream progenitors such as LRPs andMPPswere identified as lineagelow
c-Kithigh Sca-1high CD150CD48+ and lineagelow c-Kithigh Sca-1high CD150
CD48, respectively.
Microarray Experiments and Data Analysis
For each sample, HSCs sorted from 20 B6 mice were pooled, and RNA was
extracted as described above. cDNA was prepared using the Ovation Pico
WTA System V2 (NuGEN) and hybridized to GeneChip Mouse Gene 2.0 ST
arrays (Affymetrix). Raw data were normalized using the robust multi-array
average (Irizarry et al., 2003) and are available at GEO under accession number
GEO: GSE53827. We eliminated probe sets with low variance across all sam-
ples (lower quartile) and performed hierarchical clustering using Euclidian dis-
tance and Ward’s method. Differentially expressed genes were determined
using Significance Analysis of Microarrays (Tusher et al., 2001). Probe sets
with an FDR below 10% are provided in Table S1. We performed gene set
enrichment analysis (Subramanian et al., 2005) with default parameters,
except that we used class difference as a ranking metric and permuted
gene sets instead of phenotype labels. To determine how the transcriptomes
of CCR2+ andCCR2CD150+CD48 LSKs relate to gene expression in various
other hematopoietic cells, we used a previously published method (Kho et al.,
2004) based on principal components analysis to integrate our data with a
reference dataset containing expression profiles of hematopoietic cells at
different stages of differentiation (ranging from CD34 HSCs to fully differenti-
ated myeloid and lymphoid cells). Briefly, we obtained reference data from
Konuma et al. (2011) (GEO: GSE27787) and collapsed both datasets to gene
symbols, retaining only genes that were present on both arrays. We then per-
formed a principal components analysis of the reference dataset and used the
first two principal components to project both the Konuma data and our
CCR2+ and CCR2 gene expression profiles into a 2D space.
siRNA Treatment
siRNA (5-uGcuAAAcGucucuGcAAAdTsdT-3 [sense], 5-UUUGcAGAGACG
UUuAGcAdTsdT-3 [anti-sense]) against CCR2 was formulated into lipid nano-
particles as described previously (Leuschner et al., 2011). B6 mice were in-
jected intravenously with 0.5 mg/kg/day siRNA for 4 days after MI.
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